Form 4: Viridian Therapeutics Director Tomas Kiselak Granted Stock Options

Director Tomas Kiselak of Viridian Therapeutics, Inc. was granted stock options for 21,000 shares on June 26, 2024, according to a Form 4 filing.

Summary

• On June 26, 2024, Tomas Kiselak, a director of Viridian Therapeutics, Inc., was granted stock options for 21,000 shares.
• The exercise price of these options is $12.31 per share.
• The options vest either on June 26, 2025, or at the company's 2025 annual meeting of stockholders, contingent upon Kiselak's continued service on the Board.
• Kiselak holds the option for investment vehicles managed by Fairmount Funds Management LLC and will transfer any net cash or stock received to the Adviser for the benefit of a Fairmount Fund.
• Kiselak disclaims beneficial ownership of the option and underlying common stock due to this arrangement.
• A Power of Attorney was executed on June 26, 2024, granting Thomas Beetham, Seth Harmon, and Jennifer Tousignant the authority to file Forms 3, 4, and 5 on Kiselak's behalf.

Sentiment

Score: 6

Explanation: The document is neutral in tone, simply reporting a stock option grant. It's a standard corporate action, neither particularly positive nor negative.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service on the Board.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key personnel, aligning their interests with the long-term success of the company. This is a standard compensation practice.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the biotech industry.
• Companies like Regeneron, Amgen, and Biogen also utilize stock options to incentivize their directors and officers.
• The vesting schedule and exercise price are within the typical range for similar grants in comparable companies.

Stakeholder Impact

• The stock option grant could potentially impact shareholders by diluting equity if the options are exercised.
• It incentivizes the director to work towards the company's success, which could benefit all stakeholders.

Key Dates